The GMRF Clinical Trials Unit is currently recruiting for the following clinical trials in melanoma:

PROTOCOL: CA209-76K (PI: DR VICTORIA ATKINSON)

Short Title: CheckMate 76K

Protocol Title: A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy With Nivolumab Versus Placebo After Complete Resection of Stage IIB/C Melanoma

Lay Title: Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma

Click here for more information

 

PROTOCOL: CA209-7CK (PI: DR VICTORIA ATKINSON)

Protocol Title: A prospective, observational study in patients receiving adjuvant nivolumab therapy for resected melanoma in Australia

Lay Title: An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia

Click here for more information

 

PROTOCOL: CA045-022(PI: DR VICTORIA ATKINSON)

Short Title: PIVOT-12
Protocol Title: A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence
Lay Title: Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence

Click here for more information

 

RETURN TO CLINICAL TRIALS PAGE